Amicus Sets IPO Terms

Amicus Therapeutics Inc., a Cranbury, N.J.-based drug company focused on genetic diseases like Fabry disease, has set its proposed IPO terms to five million common shares being offered at between $14 and $16 per share. It plans to trade on the Nasdaq under ticker symbol FOLD, with Morgan Stanley and Merrill Lynch serving as co-lead underwriters. The company has raised around $146 million in total VC funding, including a $60 million Series D infusion late last year. Backers include New Enterprise Associates (26.3% pre-IPO stake), Frazier Healthcare Ventures (15.2%), Prospect Venture Partners (13.2%), CHL Medical Partners (12.4%), Canaan Partners (12.1%), Quaker BioVentures (8.3%), Och-Ziff Capital Management, Palo Alto Investors and Radius Ventures.